TRAVERE THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
TRAVERE THERAPEUTICS, INC. (TVTX) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent of -$34.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromContinuingOperations · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2026-06-30 was -$34.80M.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2026-03-31 was -$36.60M.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2025-12-31 was -$21.99M.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2025-09-30 was $25.71M.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2025 was -$50.26M.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2024 was -$320.63M.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2023 was -$376.33M.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2022 was -$331.47M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.80M 10-Q · filed 2026-08-04 | -$71.40M 10-Q · filed 2026-08-04 | -$93.39M derived: sum of 3 quarters · filed 2026-08-04 | -$67.68M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$36.60M 10-Q · filed 2026-05-04 | -$58.59M derived: sum of 2 quarters · filed 2026-05-04 | -$32.88M derived: sum of 3 quarters · filed 2026-05-04 | -$45.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$21.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.72M derived: sum of 2 quarters · filed 2026-02-19 | -$9.04M derived: sum of 3 quarters · filed 2026-08-04 | -$50.26M 10-K · filed 2026-02-19 |
| 2025-09-30 | $25.71M 10-Q · filed 2025-10-30 | $12.95M derived: sum of 2 quarters · filed 2026-08-04 | -$28.27M 10-Q · filed 2025-10-30 | -$88.54M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$12.76M 10-Q · filed 2026-08-04 | -$53.98M 10-Q · filed 2026-08-04 | -$114.25M derived: sum of 3 quarters · filed 2026-08-04 | -$169.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$41.23M 10-Q · filed 2026-05-04 | -$101.49M derived: sum of 2 quarters · filed 2026-05-04 | -$156.25M derived: sum of 3 quarters · filed 2026-05-04 | -$225.90M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$60.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$115.02M derived: sum of 2 quarters · filed 2026-02-19 | -$184.67M derived: sum of 3 quarters · filed 2026-02-19 | -$320.63M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$54.75M 10-Q · filed 2025-10-30 | -$124.40M derived: sum of 2 quarters · filed 2025-10-30 | -$260.36M 10-Q · filed 2025-10-30 | -$348.96M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$69.65M 10-Q · filed 2025-08-06 | -$205.61M 10-Q · filed 2025-08-06 | -$294.21M derived: sum of 3 quarters · filed 2025-08-06 | -$383.45M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$135.96M 10-Q · filed 2025-05-01 | -$224.55M derived: sum of 2 quarters · filed 2025-05-01 | -$313.80M derived: sum of 3 quarters · filed 2025-05-01 | -$415.73M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | -$88.60M 10-K · filed 2024-02-20 | -$177.84M derived: sum of 2 quarters · filed 2024-10-31 | -$279.77M derived: sum of 3 quarters · filed 2024-10-31 | -$376.33M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$89.24M 10-Q · filed 2024-10-31 | -$191.17M derived: sum of 2 quarters · filed 2024-10-31 | -$287.74M 10-Q · filed 2024-10-31 | -$373.37M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$101.93M 10-Q · filed 2024-08-01 | -$198.50M 10-Q · filed 2024-08-01 | -$284.13M derived: sum of 3 quarters · filed 2024-08-01 | -$368.19M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$96.56M 10-Q · filed 2024-05-06 | -$182.20M derived: sum of 2 quarters · filed 2024-05-06 | -$266.26M derived: sum of 3 quarters · filed 2024-05-06 | -$346.29M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$85.64M 10-K · filed 2024-02-20 | -$169.70M derived: sum of 2 quarters · filed 2024-02-20 | -$249.72M derived: sum of 3 quarters · filed 2024-02-20 | -$331.47M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$84.06M 10-K · filed 2024-02-20 | -$164.09M derived: sum of 2 quarters · filed 2024-02-20 | -$245.83M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$80.02M 10-K · filed 2024-02-20 | -$161.77M derived: sum of 2 quarters · filed 2024-02-20 | ||
| 2022-03-31 | -$81.75M 10-K · filed 2024-02-20 | |||
| 2021-12-31 | -$217.29M 10-K · filed 2024-02-20 | |||
| 2012-08-31 | -$0.03 10-Q · filed 2012-10-10 | -$0.07 10-Q · filed 2012-10-10 | ||
| 2012-05-31 | -$0.03 10-Q · filed 2012-08-08 | |||
| 2012-02-29 | -$0.14 10-K · filed 2012-05-24 | |||
| 2011-11-30 | -$3.52K 10-Q · filed 2012-01-11 | -$3.52K derived: sum of 2 quarters · filed 2012-10-10 | -$10.57K 10-Q · filed 2012-01-11 | $15.42K derived: sum of 4 quarters · filed 2012-10-10 |
| 2011-08-31 | -$0.03 10-Q · filed 2012-10-10 | -$0.07 10-Q · filed 2012-10-10 | $18.94K derived: sum of 3 quarters · filed 2012-10-10 | $13.27K derived: sum of 4 quarters · filed 2012-10-10 |
| 2011-05-31 | -$0.03 10-Q · filed 2012-08-08 | $18.94K derived: sum of 2 quarters · filed 2012-08-08 | $13.27K derived: sum of 3 quarters · filed 2012-08-08 | |
| 2011-02-28 | $18.94K derived: 10-K 12 month − 10-Q 9 month · filed 2012-05-24 | $13.27K derived: sum of 2 quarters · filed 2012-05-24 | -$0.22 10-K · filed 2012-05-24 | |
| 2010-11-30 | -$5.67K 10-Q · filed 2012-01-11 | -$18.94K 10-Q · filed 2012-01-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |